{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:54:09Z","timestamp":1785401649899,"version":"3.56.0"},"reference-count":130,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Thrombotic microangiopathy (TMA) is a rare and devastating complication of kidney transplantation, which often leads to graft failure. Posttransplant TMA (PT-TMA) may occur either de novo or as a recurrence of the disease. De novo TMA can be triggered by immunosuppressant drugs, antibody-mediated rejection, viral infections, and ischemia\/reperfusion injury in patients with no evidence of the disease before transplantation. Recurrent TMA may occur in the kidney grafts of patients with a history of atypical hemolytic uremic syndrome (aHUS) in the native kidneys. Studies have shown that some patients with aHUS carry genetic abnormalities that affect genes that code for complement regulators (CFH, MCP, CFI) and components (C3 and CFB), whereas in 10% of patients (mostly children), anti-FH autoantibodies have been reported. The incidence of aHUS recurrence is determined by the underlying genetic or acquired complement abnormality. Although treatment of the causative agents is usually the first line of treatment for de novo PT-TMA, this approach might be insufficient. Plasma exchange typically resolves hematologic abnormalities but does not improve kidney function. Targeted complement inhibition is an effective treatment for recurrent TMA and may be effective in de novo PT-TMA as well, but it is necessary to establish which patients can benefit from different therapeutic options and when and how these can be applied.<\/jats:p>","DOI":"10.1097\/tp.0000000000004585","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T04:01:31Z","timestamp":1679457691000},"page":"2329-2340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["TMA in Kidney Transplantation"],"prefix":"10.1097","volume":"107","author":[{"given":"Zahra","family":"Imanifard","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Dacc\u00f2, Ranica, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Liguori","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Dacc\u00f2, Ranica, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases Aldo e Cele Dacc\u00f2, Ranica, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.ki.5001535","article-title":"The molecular biology of thrombotic microangiopathy.","volume":"70","author":"Tsai","year":"2006","journal-title":"Kidney Int"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1503\/cmaj.160142","article-title":"Thrombotic microangiopathies: a general approach to diagnosis and management.","volume":"189","author":"Arnold","year":"2017","journal-title":"CMAJ"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jca.21248","article-title":"Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.","volume":"27","author":"George","year":"2012","journal-title":"J Clin Apher"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome.","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome.","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome.","volume":"36","author":"Mele","year":"2014","journal-title":"Semin Immunopathol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy.","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"e2010033","DOI":"10.4084\/mjhid.2010.033","article-title":"Thrombotic microangiopathy in haematopoietic cell transplantation: an update.","volume":"2","author":"Stavrou","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/TP.0000000000000525","article-title":"Factors predicting risk for antibody-mediated rejection and graft loss in highly human Leukocyte Antigen sensitized patients transplanted after desensitization.","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00007890-200203150-00017","article-title":"De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination.","volume":"73","author":"Langer","year":"2002","journal-title":"Transplantation"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP67335","article-title":"De novo thrombotic microangiopathy. An underrated complication of renal transplantation.","volume":"67","author":"Ponticelli","year":"2007","journal-title":"Clin Nephrol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation.","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/j.transproceed.2007.08.021","article-title":"Recurrence of hemolytic uremic syndrome after renal transplantation.","volume":"39","author":"Seitz","year":"2007","journal-title":"Transplant Proc"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.TP.0000085083.74065.1B","article-title":"Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.","volume":"76","author":"Artz","year":"2003","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome.","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am J Transplant"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"e13885","DOI":"10.1111\/ctr.13885","article-title":"De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: a case series.","volume":"34","author":"Roberts","year":"2020","journal-title":"Clin Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation.","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transplant Int"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States.","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation.","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","article-title":"Cyclosporine-associated thrombotic microangiopathy in renal allografts.","volume":"55","author":"Zarifian","year":"1999","journal-title":"Kidney Int"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy.","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports.","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the bloodcenter of wisconsin.","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation.","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(89)80032-0","article-title":"Renal vascular and thrombotic effects of cyclosporine.","volume":"13","author":"Remuzzi","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000020664","article-title":"Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats.","volume":"8","author":"Ram\u00edrez","year":"2000","journal-title":"Exp Nephrol"},{"key":"R34-20250604","first-page":"218","article-title":"The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients.","volume":"76","author":"Sahin","year":"2011","journal-title":"Clin Nephrol"},{"issue":"2 Suppl","key":"R35-20250604","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.1016\/j.transproceed.2004.01.027","article-title":"Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology?","volume":"36","author":"Morozumi","year":"2004","journal-title":"Transplant Proc"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/ndt\/gfl836","article-title":"Cyclosporine enhances platelet procoagulant activity.","volume":"22","author":"Tomasiak","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles.","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5500\/wjt.v8.i5.122","article-title":"Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease.","volume":"8","author":"Abbas","year":"2018","journal-title":"WJT"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1600-6143.2003.00018.x","article-title":"Sirolimus may promote thrombotic microangiopathy.","volume":"3","author":"Saikali","year":"2003","journal-title":"Am J Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1600-6143.2004.00428.x","article-title":"Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.","volume":"4","author":"Fortin","year":"2004","journal-title":"Am J Transplant"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR.","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"227S","DOI":"10.1016\/S0041-1345(03)00230-6","article-title":"Molecular actions of sirolimus: sirolimus and mTor.","volume":"35","author":"Kirken","year":"2003","journal-title":"Transplant Proc"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1600-6143.2006.01433.x","article-title":"mTOR inhibition induces endothelial progenitor cell death.","volume":"6","author":"Miriuka","year":"2006","journal-title":"Am J Transplant"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-03-0502","article-title":"Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.","volume":"10","author":"Bruns","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney.","volume":"127","author":"Keir","year":"2017","journal-title":"J Clin Invest"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state.","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb Res"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2215\/CJN.05870710","article-title":"Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies.","volume":"6","author":"Meehan","year":"2011","journal-title":"CJASN"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion\u2014from mechanism to translation.","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat Med"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/TP.0b013e31827e31c9","article-title":"Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation.","volume":"95","author":"de Vries","year":"2013","journal-title":"Transplantation"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.transproceed.2011.11.052","article-title":"Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients.","volume":"44","author":"Rane","year":"2012","journal-title":"Transplant Proc"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000321328","article-title":"De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss.","volume":"32","author":"De Keyzer","year":"2010","journal-title":"Am J Nephrol"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa010319","article-title":"BK-related polyomavirus vasculopathy in a renal-transplant recipient.","volume":"345","author":"Petrogiannis-Haliotis","year":"2001","journal-title":"N Engl J Med"},{"key":"R57-20250604","first-page":"235","article-title":"Review of thrombotic microangiopathy (TMA), and post-renal transplant TMA.","volume":"17","author":"Ardalan","year":"2006","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncpneph0609","article-title":"Parvovirus-B19-associated complications in renal transplant recipients.","volume":"3","author":"Waldman","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1681\/ASN.V101146","article-title":"Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients.","volume":"10","author":"Baid","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R60-20250604","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ki.2011.194","article-title":"Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy.","volume":"80","author":"Baid-Agrawal","year":"2011","journal-title":"Kidney Int"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1128\/JVI.79.4.2211-2220.2005","article-title":"Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation.","volume":"79","author":"Rahbar","year":"2005","journal-title":"J Virol"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015.","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/ajt.12648","article-title":"Kidney transplantation from a donor with acute kidney injury: an unexpected outcome: letter to the editor.","volume":"14","author":"Mescia","year":"2014","journal-title":"Am J Transplant"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/ajt.12297","article-title":"Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.","volume":"13","author":"Alberti","year":"2013","journal-title":"Am J Transplant"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.RV17026","article-title":"Pathogenesis of atypical hemolytic uremic syndrome.","volume":"26","author":"Yoshida","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome.","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"911","DOI":"10.5301\/jn.5000146","article-title":"Posttransplant recurrence of atypical hemolytic uremic syndrome.","volume":"25","author":"Valoti","year":"2012","journal-title":"J Nephrol"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MNH.0b013e328365b3fe","article-title":"Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.","volume":"22","author":"Noris","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-14-156","article-title":"Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report.","volume":"14","author":"Mise","year":"2013","journal-title":"BMC Nephrol"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"R76-20250604","first-page":"87","article-title":"Renal transplantation in 20 children with hemolytic-uremic syndrome.","volume":"33","author":"Eijgenraam","year":"1990","journal-title":"Clin Nephrol"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0041-1345(00)00940-4","article-title":"Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection?","volume":"32","author":"Mor","year":"2000","journal-title":"Transplant Proc"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome.","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1523-1755.2002.00543.x","article-title":"Post-transplant hemolytic-uremic syndrome.","volume":"62","author":"Ruggenenti","year":"2002","journal-title":"Kidney Int"},{"key":"R82-20250604","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5414\/CNP58077","article-title":"Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange.","volume":"58","author":"Yango","year":"2002","journal-title":"Clin Nephrol"},{"key":"R83-20250604","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0272-6386(96)90468-0","article-title":"Cyclosporine-associated thrombotic microangiopathy\/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.","volume":"28","author":"Young","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"R84-20250604","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"R85-20250604","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1111\/j.1399-3046.2011.01601.x","article-title":"Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation.","volume":"16","author":"Czubkowski","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R86-20250604","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R87-20250604","doi-asserted-by":"crossref","first-page":"115S","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients.","volume":"35","author":"Russ","year":"2003","journal-title":"Transplant Proc"},{"key":"R88-20250604","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/ctr.12170","article-title":"Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.","volume":"27","author":"Koppula","year":"2013","journal-title":"Clin Transplant"},{"key":"R89-20250604","doi-asserted-by":"crossref","first-page":"260254","DOI":"10.1155\/2013\/260254","article-title":"Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy.","volume":"2013","author":"Cicora","year":"2013","journal-title":"Case Rep Med"},{"key":"R90-20250604","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.3389\/ti.2022.10228","article-title":"Three-year outcomes in kidney transplant recipients switched from calcineurin inhibitor-based regimens to belatacept as a rescue therapy.","volume":"35","author":"Morel","year":"2022","journal-title":"Transpl Int"},{"key":"R91-20250604","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ctr.12645","article-title":"The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.","volume":"30","author":"Wu","year":"2016","journal-title":"Clin Transplant"},{"key":"R92-20250604","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2009.148","article-title":"Trombotic microangiopathy: can liver-kidney transplantation cure aHUS?","volume":"5","author":"Cheong","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"R93-20250604","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches.","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"key":"R94-20250604","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome.","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R95-20250604","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.transproceed.2019.10.015","article-title":"Atypical hemolytic uremic syndrome after kidney transplantation: lessons learned from the good, the bad, and the ugly. A case series with literature review.","volume":"52","author":"Fayek","year":"2020","journal-title":"Transplant Proc"},{"key":"R96-20250604","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00467-021-05193-7","article-title":"Early relapse of atypical hemolytic uremic syndrome following ABO-incompatible living-related pediatric kidney re-transplant successfully treated with eculizumab.","volume":"36","author":"Stojanovic","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"R97-20250604","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.","volume":"12","author":"Cugno","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R98-20250604","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"R99-20250604","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1086\/318203","article-title":"Factor H mutations in hemolytic uremic syndrome cluster in exons 18\u201320, a domain important for host cell recognition.","volume":"68","author":"Richards","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R100-20250604","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome.","author":"Glover","year":"2023","journal-title":"Transplantation"},{"key":"R101-20250604","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"R102-20250604","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series.","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R103-20250604","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.ajkd.2017.08.005","article-title":"Kidney transplantation in patients with atypical hemolytic uremic syndrome: a therapeutic dilemma (or Not)?","volume":"70","author":"Noris","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R104-20250604","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2215\/CJN.02170508","article-title":"Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.","volume":"4","author":"Saland","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R105-20250604","doi-asserted-by":"crossref","first-page":"751093","DOI":"10.3389\/fimmu.2021.751093","article-title":"Case report: combined liver-kidney transplantation to correct a mutation in complement factor B in an atypical hemolytic uremic syndrome patient.","volume":"12","author":"L\u00f3pez-Trascasa","year":"2021","journal-title":"Front Immunol"},{"key":"R106-20250604","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R107-20250604","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2015.00018","article-title":"Blood disorders typically associated with renal transplantation.","volume":"3","author":"Yang","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"R108-20250604","first-page":"455","article-title":"Cyclosporin-induced endothelial cell injury.","volume":"55","author":"Zoja","year":"1986","journal-title":"Lab Invest"},{"key":"R109-20250604","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.transproceed.2012.01.089","article-title":"Apoptosis in endothelial cells by cyclosporine.","volume":"44","author":"Hwang","year":"2012","journal-title":"Transplant Proc"},{"key":"R110-20250604","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.toxlet.2013.01.007","article-title":"Cyclosporine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission.","volume":"218","author":"de Arriba","year":"2013","journal-title":"Toxicol Lett"},{"key":"R111-20250604","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation.","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"key":"R112-20250604","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.healun.2010.08.010","article-title":"Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation.","volume":"30","author":"Ahya","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R113-20250604","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1399-0012.2012.01677.x","article-title":"Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients.","volume":"26","author":"Thibodeau","year":"2012","journal-title":"Clin Transplant"},{"key":"R114-20250604","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ndt\/gfh334","article-title":"De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases.","volume":"20","author":"Crew","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R115-20250604","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2515\/therapie\/2014020","article-title":"Sirolimus-related systemic thrombotic microangiopathy after renal transplantation.","volume":"69","author":"Negrini","year":"2014","journal-title":"Therapie"},{"key":"R116-20250604","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrneph.2009.168","article-title":"time to rethink immunosuppression by mTOR inhibitors?","volume":"5","author":"S\u00e4emann","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"R117-20250604","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in De Novo kidney transplants: an analysis from the randomized TRANSFORM study.","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"R118-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/157488606776930580","article-title":"Sirolimus early graft nephrotoxicity: clinical and experimental data.","volume":"1","author":"Pallet","year":"2006","journal-title":"Curr Drug Saf"},{"key":"R119-20250604","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-6143.2008.02482.x","article-title":"Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy.","volume":"9","author":"Ashman","year":"2009","journal-title":"Am J Transplant"},{"key":"R120-20250604","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2741\/196","article-title":"Histopathology and outcome of acute humoral rejection in renal allografts.","volume":"3","author":"Satoskar","year":"2011","journal-title":"Front Biosci (Schol Ed)"},{"key":"R121-20250604","first-page":"1727986","article-title":"De novo atypical haemolytic uremic syndrome after kidney transplantation.","volume":"2018","author":"Devresse","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"R122-20250604","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2006-939767","article-title":"Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome.","volume":"32","author":"Zimmerhackl","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R123-20250604","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference.","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"R124-20250604","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.kint.2016.06.006","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701\u2013711.","volume":"90","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"R125-20250604","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial.","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R126-20250604","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"R127-20250604","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis.","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"R128-20250604","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.","volume":"27","author":"Zuber","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"R129-20250604","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized Eculizumab therapy in hemolytic uremic syndrome.","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R130-20250604","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00467-015-3278-0","article-title":"Liver transplantation for aHUS: still needed in the eculizumab era?","volume":"31","author":"Coppo","year":"2016","journal-title":"Pediatr Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:02:52Z","timestamp":1749060172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":130,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004585","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,21]]}}}